Oxytocin Differentiated Effects According to the Administration Route in a Prenatal Valproic Acid-Induced Rat Model of Autism

• Published in: Medicina (Kaunas, Lithuania) Vol. 56; no. 6; p. 267
• Main Authors: Lefter, Radu, Ciobica, Alin, Antioch, Iulia, Ababei, Daniela Carmen, Hritcu, Luminita, Luca, Alina-Costina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 29-05-2020; MDPI AG
• Subjects: Administration, Intranasal; Analysis of Variance; Animals; Anticonvulsants - adverse effects; autism; Autism Spectrum Disorder - drug therapy; Autism Spectrum Disorder - etiology; Autism Spectrum Disorder - physiopathology; Disease Models, Animal; Drug Administration Routes - veterinary; Female; gastrointestinal disturbances; Injections, Intraperitoneal; intranasal; intraperitoneal; oxidative stress; Oxytocics - administration & dosage; Oxytocics - pharmacology; oxytocin; Oxytocin - administration & dosage; Oxytocin - pharmacology; Pregnancy; Prenatal Care - methods; Rats; Rats, Wistar; Valproic Acid - adverse effects; oxytocin; intranasal; intraperitoneal; gastrointestinal disturbances; autism; oxidative stress
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina56060267

: The hormone oxytocin (OXT) has already been reported in both human and animal studies for its promising therapeutic potential in autism spectrum disorder (ASD), but the comparative effectiveness of various administration routes, whether central or peripheral has been insufficiently studied. In the present study, we examined the effects of intranasal (IN) vs. intraperitoneal (IP) oxytocin in a valproic-acid (VPA) autistic rat model, focusing on cognitive and mood behavioral disturbances, gastrointestinal transit and central oxidative stress status.
: VPA prenatally-exposed rats (500 mg/kg; age 90 days) in small groups of 5 (
= 20 total) were given OXT by IP injection (10 mg/kg) for 8 days consecutively or by an adapted IN pipetting protocol (12 IU/kg, 20 μL/day) for 4 consecutive days. Behavioral tests were performed during the last three days of OXT treatment, and OXT was administrated 20 minutes before each behavioral testing for each rat. Biochemical determination of oxidative stress markers in the temporal area included superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA). A brief quantitative assessment of fecal discharge over a period of 24 hours was performed at the end of the OXT treatment to determine differences in intestinal transit.
: OXT improved behavioral and oxidative stress status in both routes of administration, but IN treatment had significantly better outcome in improving short-term memory, alleviating depressive manifestations and mitigating lipid peroxidation in the temporal lobes. Significant correlations were also found between behavioral parameters and oxidative stress status in rats after OXT administration. The quantitative evaluation of the gastrointestinal (GI) transit indicated lower fecal pellet counts in the VPA group and homogenous average values for the control and both OXT treated groups.
: The data from the present study suggest OXT IN administration to be more efficient than IP injections in alleviating autistic cognitive and mood dysfunctions in a VPA-induced rat model. OXT effects on the cognitive and mood behavior of autistic rats may be associated with its effects on oxidative stress. Additionally, present results provide preliminary evidence that OXT may have a balancing effect on gastrointestinal motility.